An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage)
- Conditions
- Primary Focal Segmental Glomerulosclerosis (FSGS)MedDRA version: 21.1Level: PTClassification code 10067757Term: Focal segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- EUCTR2017-003022-32-PL
- Lead Sponsor
- ChemoCentryx, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 13
1. Male or female subjects aged 18 years and older
2. Renal biopsy findings consistent with diagnosis of focal segmental glomerulosclerosis (FSGS), and consistent with primary FSGS based on presentation of histopathology, medical history, and clinical course; subjects with genetic risk factors with presentations that are otherwise consistent with primary FSGS may also be enrolled.
3. Urinary total protein:creatinine ratio (UPCR) = 3.5 g protein/g creatinine at screening, based on sample drawn from a 24-hour collection
4. Hypoalbuminemia of less than 3.5 g/dL
5. Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD_EPI) equation (using creatinine or cystatin C)
6. If used, RAAS inhibitor dose, including doses of angiotensin converting enzyme inhibitor and/or angiotensin II receptor antagonist must have been started at least 4 weeks prior to Study Day 1, and projected to remain stable throughout the course of the study unless adjustment is required for management of hypertension.
7. Female subjects of childbearing potential may participate if adequate contraception is used during, and for at least 5 half- lives after last dose of study drug. Male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least one month after the last dose of study drug. Adequate contraception is defined as resulting in a failure rate of less than 1% per year (combined estrogen and progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal contraception (oral, injectable, or implantable), intra-uterine device, intra-uterine hormone releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence). In addition, a barrier method (i.e. cervical cap, diaphragm or condom) must be used during intercourse between a male subject and a female of child-bearing potential.
8. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
9. Judged to be otherwise fit for the study by the Investigator, based on medical history, physical examination, and clinical laboratory assessments. Subjects with clinical laboratory values that are outside of normal limits (other than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance, may be entered into the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 3
1. Pregnant or nursing
2. History of organ transplantation, including renal transplantation
3. Currently on an organ transplant waiting list or there’s a reasonable possibility of getting an organ transplant within 6 months of screening
4. Histological FSGS subtype of collapsing variant
5. Subjects who initiated, discontinued or changed dose of rituximab or other anti-CD20 monoclonal antibodies within 16 weeks (4 months) prior to screening are excluded. Subjects who initiated treatment with rituximab or other anti-CD20 monoclonal antibodies >16 weeks (4 months) prior to screening are permitted if deemed safe by the investigator and only if they are intended to remain on continued, unchanged therapy at a dosing interval that has been documented to achieve continuous B cell depletion for the given patient. UPCR and other urine protein assessments up to 1 year prior to screening (if available) that were performed in these patients as part of the clinical routine should be recorded in the medical history.
6. Subjects who discontinued Rituximab or other anti-CD20 monoclonal antibodies >16 weeks (4 months) prior to screening without confirmed recovery of CD20+ B cell population to within normal range are excluded. Subjects who discontinued rituximab or other anti-CD20 monoclonal antibodies >16 weeks (4 months) prior to screening with confirmed recovery of CD20+ B cell population to within normal range are permitted in the study. UPCR and other urine protein assessments up to 1 year prior to screening (if available) that were performed in these patients as part of the clinical routine should be recorded in the medical history.
7. Subjects who initiated or increased the dose of calcineurin inhibitors, or other immunotherapy, within 12 weeks prior to screening are excluded; dose reductions to maintain calcineurin inhibitors at optimal safe levels are permitted. Subjects who initiated a treatment with calcineurin inhibitors, or other immunotherapy >12 weeks are permitted. UPCR and other urine protein assessments up to 1 year prior to screening (if available) that were performed in these patients as part of the clinical routine should be recorded in the medical history.
8. Subjects taking glucocorticoids at dose greater than 10 mg/day prednisone equivalent within 4 weeks prior to screening are excluded.
9. Plasmapheresis within 12 weeks prior to screening
10. Body Mass Index (BMI) = 40
11. Participated in any clinical study of an investigational product within 12 weeks prior to screening or within 5 half-lives after taking the last dose
12. Currently on dialysis or likely to require dialysis during the study
13. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ such as cervical or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis
14. Positive HBV, HCV, or HIV viral screening test. Subjects who have received highly effective therapy for HCV demonstrated to have negative viral titers for at least 6 months following discontinuation of treatment, will be considered to have a negative HCV screening test weeks prior to screening
15. Evidence of tuberculosis based on interferon ? release assay (IGRA), tuberculin purified protein derivative (PPD) skin test, or chest radiography done during screening or within 6 weeks prior to screening
16. Evidenc
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method